SOPHiA GENETICS reported Q4 FY 2025 revenue of USD 21.7 million, up 22.0% year-over-year, with gross margin of 67.7% (73.9% adjusted). IFRS net loss for Q4 was USD 19.2 million, while adjusted EBITDA loss was USD 9.9 million. For FY 2025, SOPHiA GENETICS posted revenue of USD 77.3 million, up 19.0% year-over-year, with gross margin of 67.4% (74.2% adjusted). IFRS net loss was USD 79.0 million and adjusted EBITDA loss was USD 41.5 million. The company guided for FY 2026 revenue of USD 92 million to USD 94 million and an adjusted EBITDA loss of USD 29 million to USD 32 million. Operationally, SOPHiA GENETICS performed more than 391,000 analyses in FY 2025 (over 105,000 in Q4) and ended 2025 with 528 core genomics customers; net dollar retention was 115%. The company signed a record 124 new core genomics customers in FY 2025 (30 in Q4), including NYU Langone Health, and said it signed two large U.S. integrated health systems expected to add about 60,000 analyses annually, ramping in the second half of 2026. In applications, it performed over 7,500 liquid biopsy analyses in FY 2025 and reported more than 70 customers signed to its MSK-ACCESS liquid biopsy application since launch; it also said it signed 21 customers to its MSK-IMPACT solid tumor applications. SOPHiA GENETICS also reported four recently signed BioPharma contracts and a global commercial agreement with a new top 5 pharmaceutical company focused on oncology, and noted USD 15.5 million in net proceeds raised via its ATM program (including USD 1.1 million in Q4 and USD 14.4 million in Q1 2026) at a weighted-average price of USD 5.12 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603030645PR_NEWS_USPR_____NE99442) on March 03, 2026, and is solely responsible for the information contained therein.